Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


12th World Cancer Conference

London, UK

Ella L Kim

Ella L Kim

Johannes Gutenberg University Medical Centre, Germany

Title: The role of stem-like glioma cells in GBM progression and post-treatment recurrence


Biography: Ella L Kim


Glioblastoma multiforme (GBM) is the most malignant intrinsic brain tumor. Th e current standard of care for newly diagnosed GBMs involves maximum safe resection, radiation therapy and concomitant/adjuvant chemotherapy with DNA alkylating agent temozolimide (TMZ). Th e effi cacy of existing therapies is unsatisfactory with a rather modest survival advantage compared to radiation treatment alone (median survival 14.6 vs. 12.2 months, respectively), <10% of the highest 5-years survival rate and inevitable post-treatment recurrence. Developing eff ective therapies for GBM previously based on the paradigm for the pathogenesis and therapeutic resistance of this devastating disease is ongoing. A new conception of GBM has emerged aft er the identifi cation of a distinct population of glioma stem-like cells (GSCs). GSCs are thought to have the highest tumorigenic potential among all cell types comprising the tumor and responsible for tumor growth aft er treatment. However, there is still considerable uncertainty regarding the precise role of GSCs in the initiation, maintenance and progression of GBM with some fundamental questions remaining. Is there a universal type of stem-like glioma cells? What criteria defi ne glioma cell stemness? How does the degree of glioma cell stemness relate to the clinicopathological criteria of glioma aggressiveness? Our research indicates that, in GBM, the type of cells collectively called GICs comprise heterogeneous subtypes of phenotypically
and functionally distinct cells with varying tumorigenic potential. Our findings urge a reconsideration of some of the key assumptions of the GIC paradigm and provide important insights into the roles of diff erent types of stem-like cells in GBM.